uniQure N.V. (NASDAQ:QURE) Files An 8-K Other Events
Item 8.01. Other Events
On January30, 2017, uniQure N.V. (the Company) issued a press
release announcing that the U.S. Food and Drug Administration
(FDA) has granted Breakthrough Therapy designation for AMT -060,
the Companys gene therapy in development for the treatment of
hemophilia B.
A copy of the press release is filed herewith as Exhibit99.1 and
is incorporated by reference herein in its entirety.
Item 9.01 Financial Statements and
Exhibits
|
(d) |
Exhibits |
|
|
99.1 |
Press release dated January30, 2017. |
About uniQure N.V. (NASDAQ:QURE)
uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease. Its product candidates include AMT-060 for Hemophilia B, AMT-110 for Sanfilippo B Syndrome, AAV2/GDNF for Parkinson’s Disease, S100A1 for Congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). For the AMT-060, the Company is conducting a Phase I/II clinical trial. The AMT-110 is based on glial cell line-derived neurotrophic factor, which is being studied in an investigator-sponsored Phase I clinical study. The AMT-130 is used for the treatment of Huntington’s disease, in which the Company has demonstrated preclinical proof of concept. uniQure N.V. (NASDAQ:QURE) Recent Trading Information
uniQure N.V. (NASDAQ:QURE) closed its last trading session up +0.10 at 5.47 with 108,806 shares trading hands.
